FSD Pharma : announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis. The Report Shows Compound to be Safe and Well Tolerated - Form 6-K -November 07, 2023 at 10:33 am EST

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS for Multiple Sclerosis. The Report Shows Compound to be Safe and Well Tolerated


Toronto,...

Related Keywords

Toronto ,Ontario ,Canada ,United States ,Canadian ,Zeeshan Saeed ,Lakshmip Kotra ,Andrzej Chruscinski ,Scientific Affairs At Lucid Psycheceuticals ,Biopharma Services Inc ,National Multiple Sclerosis Society ,Exchange Commission ,Lucid Psychss Inc ,Neither The Canadian Securities Exchange ,Company Annual Report On Form ,Nasdaq ,Pharma Inc ,Interim Results ,First In Human Clinical Trial ,Report Shows Compound ,Multiple Sclerosis ,Biopharma Services ,Vice President Clinical ,Scientific Affairs ,Lucid Psycheceuticals ,Psychss Inc ,Canadian Securities Administrators ,Annual Report ,Canadian Securities Exchange ,Executive Co Chairman ,Markets ,